CA
NZ
UK
AU
IND
US
Liquidia Corporation (NASDAQ:LQDA) sells Yutrepia, an inhaled dry-powder form of treprostinil approved in 2025 for pulmonary arterial hypertension and for pulmonary hypertension associated with interstitial lung disease, known as PH-ILD. The '327 patent covers methods of treating PH-ILD with inhaled treprostinil and certain dry-powder …
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) develops molecular glue degraders, small molecules that make cells destroy a chosen protein. MRT-8102 targets NEK7, a protein required for the NLRP3 inflammasome, an immune complex that drives release of IL-1 and IL-6 and, in turn, C-reactive protein. High-sensitivity …
Apimeds Pharmaceuticals US, Inc. (NYSEAMERICAN:APUS) listed through an initial public offering in May 2025 to develop biologic, non-opioid treatments for pain. In December 2025 it merged with MindWave Innovations, which offers corporate bitcoin treasury wallets, AI-enhancedYieldand a validator ecosystem built around the NILA token. …
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) develops oral, non-statin medicines for cardiovascular risk. SPINOZA is randomized, double-blind and placebo-controlled, and it enrolls adults with biomarker evidence suggestive of preclinical Alzheimer's who have no noticeable memory or functional symptoms. CEO Michael Davidson called the first dosing …
Sagimet Biosciences Inc. (NASDAQ:SGMT) is selling all securities itself. The 8,750,010 shares and 2,750,010 pre-funded warrants total about 11.5 million shares, which at USD 10 equals the USD 115.0 million raise. Pre-funded warrants are exercisable immediately for USD 0.0001, which lets large holders stay …
Moderna, Inc. (NASDAQ:MRNA) shares traded near USD 62 on August 18 and reached an intraday high of USD 208 on September 25. The rally followed news that the company and Merck (NYSE:MRK) reported that the personalized cancer vaccine intismeran autogene, combined with Keytruda, met …
Wednesday's session brought a sharp rebound for Capricor Therapeutics, Inc. (NASDAQ: CAPR), the Duchenne muscular dystrophy (DMD) cell-therapy developer. The stock gapped about 17% higher at the open after late-Tuesday 24-month data from the pivotal Phase 3 HOPE-3 trial and an analyst upgrade, and …
Wednesday's session delivered a sharp relief bounce for Inventiva S.A. (NASDAQ: IVA), the French clinical-stage biotech developing lanifibranor for MASH. After a three-week slide of nearly 40%, the stock opened above Tuesday's close and climbed 8.7% to $3.58 on heavy volume. Buyers pushed price …
Wednesday's session delivered a vertical breakout for Pacific Biosciences of California, Inc. (NASDAQ: PACB). The genomics-tools stock cleared a months-long ceiling near $1.80-$1.84 in one candle and closed at $2.42, its highest level since the January double top. Shares jumped sharply in the afternoon …
NewAmsterdam Pharma Co N.V. (NASDAQ:NAMS) announced on September 29, 2026 that the first participant has been dosed in SPINOZA, a Phase 2b trial of its oral cholesterol drug candidate obicetrapib in people with preclinical Alzheimer's disease. The company furnished the announcement in a Form …
Please wait processing your request...